Alexion Pharmaceuticals (ALXN)
$130.77 1.62 (1.22%)
11:20 EDT ALXN Stock Quote Delayed 15 Minutes
Previous Close $132.39
Market Cap 29.10B
PE Ratio 56.12
Volume (Avg. Vol.) 544,562
Day's Range 128.81 - 132.77
52-Week Range 92.56 - 141.86
Dividend & Yield N/A (N/A)
ALXN Stock Predictions, Articles, and Alexion Pharmaceuticals News
- From InvestorPlace
- From the Web
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Even in these unstable times, there are still gems to be found. These 10 stocks share a "strong buy" analyst consensus rating from the Street and compelling growth drivers.
These 10 smart money stocks to buy have significant support from top analysts. Here's why each should help you flourish throughout the rest of the year.
With stocks trading at record levels, it can be difficult to identify the best stocks to buy now. Here are 10 picks that the experts have faith in.
Here are some stocks trading near their 52-week high levels with potential to scale higher. Compare Brokers....
Stock charts of Express Scripts, Ventas and Alexion Pharmaceuticals are shaping up as your best bets as the week nears its end.
These 7 stock picks all boast support from the Street's top analysts. If you are looking to actually make money these are the stocks I recommend snapping up now. Here I also include price targets from the Street so you can see the kind of growth potential these gems have in store.
Yes the market is tricky right now. But Goldman Sachs has a report on stocks with the potential to explode. Here I single out the stocks with a 'Strong Buy' analyst consensus and see just why they are so compelling.
A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut.
Alexion stock has come under fire lately, but the company has a promising pipeline of orphan drugs that could prod others to consider a takeover.
Alexion Pharmaceuticals (ALXN) stock was up today on positive results for a recent Phase 3 clinical study for the drug ALXN1210.
Biotech's luck is changing as the trend looks to be upward and outward for the biotech stocks. These are the five to watch.
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) is a $26.3 billion in market value component of the Biotechnology GICS industry group where The current Portfolio Grader ranking for ALXN puts it 207 among the 349 companies in this industry group, which is a below-average position. ALXN is ranked in the third quartile of the sector with a ranking of 480 among the 785 companies in the sector and number 3,109 in the 5000 company Portfolio Grader company universe.
Major Biotech companies report mixed Q3 results.
A number of technical indicators are weakening or flashing warning signals for biotech stocks, and these five stand out as some of the most vulnerable.
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.
The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.
From Market News Video
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!